FDA Keeps Sweetheart Deal With Big Pharma That Limits Access to Cheaper Morning-After Pill

Think Progress argues that the FDA’s decision to grant Teva three years of exclusivity over its emergency contraceptive pill and bar generic versions to women under age 17 will ultimately block access to affordable morning-after alternatives for young women.
Think Progress